STOCK TITAN

Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2021 Financial Results, and Host Conference Call on March 15, 2022

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Kamada Ltd. (NASDAQ: KMDA) will release its financial results for Q4 and FY 2021 on March 15, 2022. A conference call for investors will follow at 8:30 AM ET, where management will discuss results and answer questions. Kamada is a leader in the plasma-derived biopharmaceutical industry, focusing on expanding its product portfolio, including FDA-approved treatments like GLASSIA® and CYTOGAM®. The company aims to drive growth through robust development and manufacturing capabilities.

Positive
  • Kamada has a diverse portfolio of FDA-approved products, including GLASSIA® and CYTOGAM®.
  • The company is conducting a pivotal Phase 3 trial for an inhaled AAT treatment.
Negative
  • None.

REHOVOT, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2021, prior to the open of the U.S. financial markets on Tuesday, March 15, 2022.

Kamada management will host an investment community conference call on Tuesday, March 15, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-407-0792 (from within the U.S.), 1 809-406-247 (from Israel), or 201-689-8263 (International) and entering the conference identification number: 13727620. The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1533883&tp_key=876a5d54ec

The call will also be archived for 90 days on the Company’s website at www.kamada.com

About Kamada

Kamada Ltd. (the “Company”) is a global leader in the plasma-derived hyperimmune market and a specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company’s strategy is to evolve into a fully integrated specialty plasma company, with a core focus on driving profitable growth from our current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical market. The Company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRRAB® as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. The Company has additional four plasma-derived products which are registered in markets outside the U.S. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has a diverse portfolio of development pipeline products including an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added nine biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2025. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com 

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
Bob@LifeSciAdvisors.com 


FAQ

When will Kamada Ltd. release its Q4 2021 financial results?

Kamada Ltd. will release its Q4 2021 financial results on March 15, 2022.

What time is the conference call for Kamada's Q4 2021 results?

The conference call will take place at 8:30 AM ET on March 15, 2022.

What products does Kamada Ltd. offer?

Kamada offers a range of plasma-derived products, including GLASSIA® and CYTOGAM®.

What is the focus of Kamada's clinical trials?

Kamada is focused on developing treatments for AAT deficiency, with a Phase 3 trial currently underway.

Kamada Ltd

NASDAQ:KMDA

KMDA Rankings

KMDA Latest News

KMDA Stock Data

335.73M
31.20M
7.31%
50.1%
0.05%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Rehovot